BUZZ-联想生物技术公司第三季度亏损收窄，业绩增长

路透中文

Nov 12, 2025

BUZZ-<a href="https://laohu8.com/S/00992">联想</a>生物技术公司第三季度亏损收窄，业绩增长

11月12日 - ** 联想生物LEGN.O第三季度财报发布后，股价上涨1.1%至32.25美元 (link)

** 由于CARVYKTI销售强劲，合作收入同比增长83%，达到2.618亿美元；许可收入从1710万美元下降到1050万美元。

** 调整后净亏损从去年同期的 4200 万美元大幅降至 1880 万美元

** FDA和欧盟批准更新CARVYKTI标签，纳入生存获益数据；公司预计CARVYKTI将在年底实现盈利，并在2026年实现整体盈利

** 截至 9 月 30 日的现金和定期存款约为 10 亿美元，公司称这为 2026 年以后的发展提供了空间

** 截至上次收盘，LEGN 累计下跌 1.57

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582808308"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582808308\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582808308?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-12 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582808308","market":"us","top_or_hot":-1,"title":"BUZZ-联想生物技术公司第三季度亏损收窄，业绩增长","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/00992\">联想</a>生物技术公司第三季度亏损收窄，业绩增长</title></head><body><p>\n<span>11月12日</span><span> - </span>** 联想<a href=\"https://laohu8.com/S/000504\">生物</a><span>LEGN.O</span>第三季度财报发布后，股价上涨1.1%至32.25美元  (<span>link</span>) </p><p>** 由于CARVYKTI销售强劲，合作收入同比增长83%，达到2.618亿美元；许可收入从1710万美元下降到1050万美元。</p><p>** 调整后净亏损从去年同期的 4200 万美元大幅降至 1880 万美元</p><p>** FDA和欧盟批准更新CARVYKTI标签，纳入生存获益数据；公司预计CARVYKTI将在年底实现盈利，并在2026年实现整体盈利</p><p>** 截至 9 月 30 日的现金和定期存款约为 10 亿美元，公司称这为 2026 年以后的发展提供了空间</p><p>** 截至上次收盘，LEGN 累计下跌 1.57</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-联想生物技术公司第三季度亏损收窄，业绩增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-联想生物技术公司第三季度亏损收窄，业绩增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-12 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/00992\">联想</a>生物技术公司第三季度亏损收窄，业绩增长</title></head><body><p>\n<span>11月12日</span><span> - </span>** 联想<a href=\"https://laohu8.com/S/000504\">生物</a><span>LEGN.O</span>第三季度财报发布后，股价上涨1.1%至32.25美元  (<span>link</span>) </p><p>** 由于CARVYKTI销售强劲，合作收入同比增长83%，达到2.618亿美元；许可收入从1710万美元下降到1050万美元。</p><p>** 调整后净亏损从去年同期的 4200 万美元大幅降至 1880 万美元</p><p>** FDA和欧盟批准更新CARVYKTI标签，纳入生存获益数据；公司预计CARVYKTI将在年底实现盈利，并在2026年实现整体盈利</p><p>** 截至 9 月 30 日的现金和定期存款约为 10 亿美元，公司称这为 2026 年以后的发展提供了空间</p><p>** 截至上次收盘，LEGN 累计下跌 1.57</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4S3WO14Y:1","article_id":"2582808308","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582808308","pubTimestamp":1762960033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"11月12日 - ** 联想生物LEGN.O第三季度财报发布后，股价上涨1.1%至32.25美元   ** 由于CARVYKTI销售强劲，合作收入同比增长83%，达到2.618亿美元；许可收入从1710万美元下降到1050万美元。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01548":"金斯瑞生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LEGN":"传奇生物","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","BK4588":"碎股","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"BUZZ-Lenovo Biotech's Q3 Loss Narrows, Results Rise","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":0.9,"01548":0.9},"content_text":"BUZZ-联想生物技术公司第三季度亏损收窄，业绩增长\n11月12日 - ** 联想生物LEGN.O第三季度财报发布后，股价上涨1.1%至32.25美元  (link) ** 由于CARVYKTI销售强劲，合作收入同比增长83%，达到2.618亿美元；许可收入从1710万美元下降到1050万美元。** 调整后净亏损从去年同期的 4200 万美元大幅降至 1880 万美元** FDA和欧盟批准更新CARVYKTI标签，纳入生存获益数据；公司预计CARVYKTI将在年底实现盈利，并在2026年实现整体盈利** 截至 9 月 30 日的现金和定期存款约为 10 亿美元，公司称这为 2026 年以后的发展提供了空间** 截至上次收盘，LEGN 累计下跌 1.57(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}